Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2020

01-08-2020 | Gallbladder Cancer | Hepatobiliary Tumors

The Landmark Series: Gallbladder Cancer

Authors: Adriana C. Gamboa, MD, MS, Shishir K. Maithel, MD

Published in: Annals of Surgical Oncology | Issue 8/2020

Login to get access

Abstract

Given the rarity of gallbladder carcinoma, level I evidence to guide the multimodal treatment of this disease is lacking. Since 2010, four randomized phase III clinical trials including ABC-02, PRODIGE-12/ACCORD-18, BILCAP, and BCAT, and a single-arm phase II trial (SWOG0809) have been reported on the use of adjuvant strategies for biliary malignancies. These trials have led to the recommendation that patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy and those with R1 margins could be considered for chemoradiotherapy. Because there is no level I evidence to guide neoadjuvant therapy or surgical management, current consensus is based on strong retrospective data. The following review summarizes available trials and highlights the best available evidence that form the basis of consensus statements for the multimodal management of gallbladder carcinoma.
Literature
1.
Henley SJ, Weir HK, Jim MA, et al. Gallbladder cancer incidence and mortality, United States 1999–2011. Cancer Epidemiol Biomark Prev. 2015;24:1319–26.
2.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
3.
Diehl AK, Beral V. Cholecystectomy and changing mortality from gallbladder cancer. Lancet. 1981;2:187–9.PubMed
4.
Saranga Bharathi R, Singh R, Gupta R, et al. Female sex hormone receptors in gallbladder cancer. J Gastrointest Cancer. 2015;46:143–8.PubMed
5.
Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118:1591–602.PubMed
6.
Roa I, Araya JC, Villaseca M, et al. Gallbladder cancer in a high risk area: morphological features and spread patterns. Hepatogastroenterology. 1999;46:1540–6.PubMed
7.
Diehl AK. Gallstone size and the risk of gallbladder cancer. JAMA. 1983;250:2323–6.PubMed
8.
Lowenfels AB, Walker AM, Althaus DP, et al. Gallstone growth, size, and risk of gallbladder cancer: an interracial study. Int J Epidemiol. 1989;18:50–4.PubMed
9.
10.
11.
12.
Akyurek N, Irkorucu O, Salman B, et al. Unexpected gallbladder cancer during laparoscopic cholecystectomy. J Hepatobiliary Pancreat Surg. 2004;11:357–61.PubMed
13.
Ethun CG, Le N, Lopez-Aguiar AG, et al. Pathologic and prognostic implications of incidental versus nonincidental gallbladder cancer: a 10-institution study from the United States Extrahepatic Biliary Malignancy Consortium. Am Surg. 2017;83:679–86.PubMedPubMedCentral
14.
Zaidi MY, Maithel SK. Updates on gallbladder cancer management. Curr Oncol Rep. 2018;20:21.PubMed
15.
Pawlik TM, Gleisner AL, Vigano L, et al. Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection. J Gastrointest Surg. 2007;11:1478–86 (discussion 1486-7).PubMed
16.
Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinomas of the gallbladder. Results of the French Surgical Association Survey. Ann Surg. 1994;219:275–80.PubMedPubMedCentral
17.
Wilkinson DS. Carcinoma of the gall-bladder: an experience and review of the literature. Aust N Z J Surg. 1995;65:724–7.PubMed
18.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.PubMed
19.
(U.S.) NCCN: Hepatobiliary cancer (version 4.2019).
20.
Oikarinen H. Diagnostic imaging of carcinomas of the gallbladder and the bile ducts. Acta Radiol. 2006;47:345–58.PubMed
21.
Bach AM, Loring LA, Hann LE, et al. Gallbladder cancer: can ultrasonography evaluate extent of disease? J Ultrasound Med. 1998;17:303–9.PubMed
22.
Levy AD, Murakata LA, Rohrmann CA Jr. Gallbladder carcinoma: radiologic–pathologic correlation. Radiographics. 2001;21:295–314 (questionnaire, 549–55).PubMed
23.
Cha SY, Kim YK, Min JH, et al. Usefulness of noncontrast MRI in differentiation between gallbladder carcinoma and benign conditions manifesting as focal mild wall thickening. Clin Imaging. 2019;54:63–70.PubMed
24.
Rodriguez-Fernandez A, Gomez-Rio M, Medina-Benitez A, et al. Application of modern imaging methods in diagnosis of gallbladder cancer. J Surg Oncol. 2006;93:650–64.PubMed
25.
Weber SM, DeMatteo RP, Fong Y, et al. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg. 2002;235:392–9.PubMedPubMedCentral
26.
Aloia TA, Jarufe N, Javle M, et al. Gallbladder cancer: expert consensus statement. HPB (Oxford). 2015;17:681–90.PubMedCentral
27.
Vigano L, Ferrero A, Amisano M, et al. Comparison of laparoscopic and open intraoperative ultrasonography for staging liver tumours. Br J Surg. 2013;100:535–42.PubMed
28.
Shindoh J, de Aretxabala X, Aloia TA, et al. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015;261:733–9.PubMedPubMedCentral
29.
Lee H, Choi DW, Park JY, et al. Surgical strategy for T2 gallbladder cancer according to tumor location. Ann Surg Oncol. 2015;22:2779–86.PubMed
30.
Duffy A, Capanu M, Abou-Alfa GK, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008;98:485–9.PubMed
31.
Foster JM, Hoshi H, Gibbs JF, et al. Gallbladder cancer: defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol. 2007;14:833–40.PubMed
32.
Fuks D, Regimbeau JM, Le Treut YP, et al. Incidental gallbladder cancer by the AFC-GBC-2009 Study Group. World J Surg. 2011;35:1887–97.PubMed
33.
Hari DM, Howard JH, Leung AM, et al. A 21-year analysis of stage I gallbladder carcinoma: is cholecystectomy alone adequate? HPB (Oxford). 2013;15:40–8.PubMed
34.
Principe A, Del Gaudio M, Ercolani G, et al. Radical surgery for gallbladder carcinoma: possibilities of survival. Hepatogastroenterology. 2006;53:660–4.PubMed
35.
D’Angelica M, Dalal KM, DeMatteo RP, et al. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009;16:806–16.PubMed
36.
Downing SR, Cadogan KA, Ortega G, et al. Early-stage gallbladder cancer in the surveillance, epidemiology, and end results database: effect of extended surgical resection. Arch Surg. 2011;146:734–8.PubMed
37.
Shih SP, Schulick RD, Cameron JL, et al. Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg. 2007;245:893–901.PubMedPubMedCentral
38.
Gani F, Buettner S, Margonis GA, et al. Assessing the impact of common bile duct resection in the surgical management of gallbladder cancer. J Surg Oncol. 2016;114:176–80.PubMedPubMedCentral
39.
Jensen EH, Abraham A, Jarosek S, et al. Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer. Surgery. 2009;146:706–11 (discussion 711-3).PubMed
40.
Ito H, Ito K, D’Angelica M, et al. Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg. 2011;254:320–5.PubMed
41.
Kondo S, Nimura Y, Hayakawa N, et al. Regional and para-aortic lymphadenectomy in radical surgery for advanced gallbladder carcinoma. Br J Surg. 2000;87:418–22.PubMed
42.
Hu J-B, Sun X-N, Xu J, et al. Port site and distant metastases of gallbladder cancer after laparoscopic cholecystectomy diagnosed by positron emission tomography. World J Gastroenterol. 2008;14:6428–31.PubMedPubMedCentral
43.
Z’Graggen K, Birrer S, Maurer CA, et al. Incidence of port site recurrence after laparoscopic cholecystectomy for preoperatively unsuspected gallbladder carcinoma. Surgery. 1998;124:831–8.PubMed
44.
Maker AV, Butte JM, Oxenberg J, et al. Is port site resection necessary in the surgical management of gallbladder cancer? Ann Surg Oncol. 2012;19:409–17.PubMed
45.
Fuks D, Regimbeau JM, Pessaux P, et al. Is port-site resection necessary in the surgical management of gallbladder cancer? J Visc Surg. 2013;150:277–84.PubMed
46.
Ethun CG, Postlewait LM, Le N, et al. Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. J Surg Oncol. 2017;115:805–11.PubMedPubMedCentral
47.
Ethun CG, Postlewait LM, Le N, et al. Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. JAMA Surg. 2017;152:143–9.PubMedPubMedCentral
48.
Goere D, Wagholikar GD, Pessaux P, et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc. 2006;20:721–5.PubMed
49.
Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–700.PubMed
50.
Nakachi K, Konishi M, Ikeda M, et al. A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT). Jpn J Clin Oncol. 2018;48:392–5.PubMed
51.
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.PubMed
52.
Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized Phase III study. J Clin Oncol. 2019;37:658–67.PubMed
53.
Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–73.PubMed
54.
Malka D, Edeline J. Adjuvant capecitabine in biliary tract cancer: a standard option? Lancet Oncol. 2019;20:606–8.PubMed
55.
Ebata T, Hirano S, Konishi M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192–202.PubMed
56.
Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2006;66:772–9.PubMed
57.
Czito BG, Hurwitz HI, Clough RW, et al: Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys. 2005;62:1030–4.PubMed
58.
Kresl JJ, Schild SE, Henning GT, et al. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys. 2002;52:167–75.PubMed
59.
Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a Phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33:2617–22.PubMed
60.
Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37:1015–27.PubMed
61.
Hakeem AR, Papoulas M, Menon KV. The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer: a systematic review. Eur J Surg Oncol. 2019;45:83–91.PubMed
62.
63.
Iyer P, Shrikhande SV, Ranjan M, et al. ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer. Int J Cancer. 2019;144:2008–19.PubMed
64.
Lin J, Dong K, Bai Y, et al. Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice. Ann Transl Med. 2019;7:467.PubMedPubMedCentral
Metadata
Title
The Landmark Series: Gallbladder Cancer
Authors
Adriana C. Gamboa, MD, MS
Shishir K. Maithel, MD
Publication date
01-08-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 8/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08654-9

Other articles of this Issue 8/2020

Annals of Surgical Oncology 8/2020 Go to the issue

Melanoma

Outcomes of Immunosuppressed Patients Who Develop Melanoma: A Population-Based Propensity-Matched Cohort Study

ASO Author Reflections

ASO Author Reflections: Could Ovarian Preservation be Considered for Young Women with Endometrial Cancer?

Colorectal Cancer

Selection of Patients for Organ Preservation After Chemoradiotherapy: It Is Too Early to Exclude Any Method for Assessment of Response After CRT

Health Services Research and Global Oncology

The Influence of Comorbidity on Health-Related Quality of Life After Esophageal Cancer Surgery

Health Services Research and Global Oncology

Time to Adjuvant Radiotherapy in Breast Cancer Affects Survival: Implications for the American College of Surgeons Commission on Cancer Quality Metrics

Health Services Research and Global Oncology

COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission